Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

June 06, 2007 09:00 ET

Urodynamix Reports 2007 Annual Meeting Results

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 6, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce the results of its Annual and Special Meeting ("the Meeting") held June 4, 2007.

Mr. Pierre Leduc was elected to the board of directors. Mr. Leduc is principal of Leduc Associates Management Consultants, a firm specializing in biotechnology companies. Prior to forming his consultancy, Mr. Leduc served as President and CEO of Neurostream Technologies Inc. and was Chairman of Xillix Technologies Corp. Earlier in his career, Mr. Leduc had a 20-year association with Baxter Corporation in many executive capacities, including President of Baxter Corporation Canada. Mr. Leduc currently serves on the Board of Directors of Providence Health Care and Ondine Biopharma Inc. of Vancouver, BC and Novx Systems Inc. of Markham, Ontario.

The shareholders re-elected Mr. Jim Heppell, Mr. Paul Geyer, Dr. Zeid Mohamedali and Mr. Barry Allen as directors of the Company, and the number of directors was set at five.

The shareholders approved the Company's Stock Option Plan as required by the TSX Venture Exchange, and Berris Mangan, Chartered Accountants was re-appointed as the auditor for the Company for the ensuing year.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urological conditions in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company's disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

Barry Allen, President & CEO

Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information